Yesterday, JPMorgan Chase (NYSE: JPM) reported that the bank's second-quarter earnings fell as a result of adding $428 million in bad loan reserves.
With this view, JPMorgan has chosen to temporarily halt its share repurchases in order to meet regulatory capital requirements.
According to a statement from JPMorgan, the reserve rise was primarily to blame for the earnings decline of 28% from a year earlier to $8.65 billion. Additionally, JPMorgan, which has one of the largest operations on Wall Street, was hurt by the slowdown in Wall Street transactions. Investment banking fees dropped sharply by 54% to $1.65 billion, $250 million less than the forecasted $1.9 billion.
Fixed income trading revenue increased by 15% to $4.71 billion, Although it still fell far short of analysts' expectations of $5.14 billion for the quarter while strong results in macro trading were offset by a decline in credit and securitized products, resulting in a quarter-end revenue that was far below analysts' $5.14 billion projection.
On the positive side of its report, revenue from equity trading increased by 15% to $3.08 billion, beating the estimate of $2.96 billion. Rising U.S. interest rates and a growing book of loans are two positive factors for the firm. For the quarter, net interest income increased by 19% to $15.2 billion, exceeding analysts' expectations of $14.98 billion. JPMorgan stated during the firm's investor day in May that rising rates will allow it to surpass its main goal of 17% returns this year faster than anticipated. However, the firm has achieved that goal this month.
JPM stock dropped about 5% in intra-day trading on Thursday but found the support to finally settle only 3.5% lower at closing. JPM now trades at a 90-week low, but with a rumored 100 basis-points rate hike due from the US Federal Reserve within a couple weeks, perhaps bank stocks will find their bottom before the rest of the market.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.